Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation-Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy.

JMIR Res Protoc · 2024 · PMC11252616 · PMID 38954434

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

For the number of comorbidities, national electronic health databases and clinical records differed on average by <1 comorbidity but with a marginally significant P value of .03 and 95% CIs almost overlapping with zero difference.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.